Janssen Halts the Development of Pimodivir for Influenza

Shots:

• The discontinuation is based on pre-planned interim analyses of P-III studies assessing Pimodivir + SOC vs SOC as monothx. in hospitalized & non-hospitalized patients with influenza A
• The therapy is unlikely to add benefits in hospitalized patients with influenza A. The company will halt both the studies, after consulting with BARDA
• In 2014, Janssen signed an exclusive license agreement with Vertex for the global development, manufacturing, and commercialization of pimodivir

Click here ­to­ read full press release/ article | Ref: Janssen | Image: Philadelphia Inquirer